Quarterly report pursuant to Section 13 or 15(d)

Debt - Narrative (Details)

v3.8.0.1
Debt - Narrative (Details)
1 Months Ended 3 Months Ended 9 Months Ended 48 Months Ended
Aug. 07, 2017
USD ($)
Mar. 17, 2017
USD ($)
Feb. 01, 2017
USD ($)
$ / shares
Nov. 05, 2015
USD ($)
Apr. 01, 2015
d
conversion_right
$ / shares
Jan. 30, 2013
USD ($)
d
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
Sep. 30, 2017
USD ($)
institution
$ / shares
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
institution
Dec. 31, 2016
USD ($)
institution
shares
Debt Instrument [Line Items]                        
Gain on embedded derivative             $ 3,200,000   $ 5,100,000 $ 4,900,000    
Fair value of embedded derivative     $ 13,600,000       $ 13,600,000          
Reversal of gains on embedded derivative               $ 6,800,000     $ 6,800,000  
Gain on derivative impact on loss per share (in dollars per share) | $ / shares               $ (0.01)        
Credit line capacity               $ 196,809,000     196,809,000  
Goodwill               $ 715,573,000     $ 715,573,000 $ 704,603,000
Number of financial institutions | institution               11     11 10
BioReference                        
Debt Instrument [Line Items]                        
Net assets               $ 1,000,000,000     $ 1,000,000,000  
Goodwill               401,800,000     401,800,000  
Intangible assets               $ 457,000,000     $ 457,000,000  
OPKO Health Europe                        
Debt Instrument [Line Items]                        
Weighted average interest rate               2.90%     2.90% 3.20%
Minimum | OPKO Health Europe                        
Debt Instrument [Line Items]                        
Variable interest rates               1.80%     1.80%  
Maximum | OPKO Health Europe                        
Debt Instrument [Line Items]                        
Variable interest rates               6.30%     6.30%  
Senior Notes                        
Debt Instrument [Line Items]                        
Fair value of embedded derivative               $ 0     $ 0 $ 16,736,000
Reclassification of embedded derivatives to equity                     $ 13,551,000  
Senior Notes | Notes Due February 1, 2033                        
Debt Instrument [Line Items]                        
Debt face amount           $ 175,000,000.0            
Interest rate on notes payable           3.00%            
Equivalent redemption price           100.00%            
Notes | Notes Due February 1, 2033                        
Debt Instrument [Line Items]                        
Equivalent redemption price           100.00%            
Conversion price per share (in dollars per share) | $ / shares     $ 7.07   $ 7.07 $ 7.07 $ 7.07          
Convertible debt, threshold percentage of stock price trigger         130.00% 130.00%            
Number of trading days | d         20              
Conversion rate     0.1414827   0.1414827 0.14148            
Number of consecutive trading days applicable conversion price | d         30              
Conversion right triggered | conversion_right         1              
Common stock trigger price (in dollars per share) | $ / shares         $ 9.19              
Notes | Notes Due February 1, 2033 | Minimum                        
Debt Instrument [Line Items]                        
Number of trading days | d           20            
Notes | Notes Due February 1, 2033 | Maximum                        
Debt Instrument [Line Items]                        
Number of consecutive trading days applicable conversion price | d           30            
Notes | Notes Due February 1, 2033 | On or after February 1, 2017 and before February 1, 2019                        
Debt Instrument [Line Items]                        
Equivalent redemption price           100.00%            
Notes | Notes Due February 1, 2033 | On or after February 1, 2019                        
Debt Instrument [Line Items]                        
Equivalent redemption price           100.00%            
Convertible Debt | Notes Due February 1, 2033                        
Debt Instrument [Line Items]                        
Converted debt amount                       $ 143,200,000.0
Line of Credit                        
Debt Instrument [Line Items]                        
Weighted average interest rate               4.50%     4.50% 4.70%
Revolving Credit Facility | Line of Credit | New Credit Agreement                        
Debt Instrument [Line Items]                        
Credit line capacity       $ 175,000,000.0                
Higher borrowing capacity option       $ 275,000,000.0                
Commitment fee percentage       0.50%                
Maximum intercompany loan $ 35,000,000 $ 55,000,000                    
Swingline | Line of Credit | New Credit Agreement                        
Debt Instrument [Line Items]                        
Credit line capacity       $ 20,000,000.0                
Letter of Credit | Line of Credit | New Credit Agreement                        
Debt Instrument [Line Items]                        
Credit line capacity       $ 20,000,000.0                
LIBOR | Revolving Credit Facility | Line of Credit | New Credit Agreement                        
Debt Instrument [Line Items]                        
Basis spread on variable rate       2.50%                
LIBOR, First 12 Months | Revolving Credit Facility | Line of Credit | New Credit Agreement                        
Debt Instrument [Line Items]                        
Basis spread on variable rate       0.35%                
LIBOR Thereafter | Revolving Credit Facility | Line of Credit | New Credit Agreement                        
Debt Instrument [Line Items]                        
Basis spread on variable rate       0.50%                
LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                        
Debt Instrument [Line Items]                        
Basis spread on variable rate       1.35%                
LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                        
Debt Instrument [Line Items]                        
Basis spread on variable rate       1.50%                
Common Stock | Convertible Debt | Notes Due February 1, 2033                        
Debt Instrument [Line Items]                        
Shares issued on converted debt (in shares) | shares                       21,539,873
Additional Paid-in Capital                        
Debt Instrument [Line Items]                        
Reclassification of embedded derivatives to equity                     $ 13,600,000